Adelaide, Australia, 14th July 2025 GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to…
On 12 June 2025, GPN AUS and GPN USA signed a Deed of Variation to the Scheme Implementation…
Canberra, Australia, 27th May 2025 GPN Vaccines Ltd is pleased to announce the Company’s shareholders have voted unanimously…
Adelaide, Australia, 12 th November 2024 – GPN Vaccines Ltd is pleased to announce that dose escalation has…
Adelaide, Australia, 17th October 2024 – GPN Vaccines Ltd is thrilled to announce the appointment of Dr. Bruce…
Adelaide, Australia, 5th September 2024 – GPN Vaccines Ltd is pleased to announce that the first participant has…
Adelaide, Australia, 21st August 2024 GPN Vaccines is pleased to announce it has received ethics approval to commence…
Adelaide, Australia, 6th June 2024 – GPN Vaccines is pleased to announce the closing of its oversubscribed Series…
Adelaide, Australia – 7th May 2024 GPN Vaccines Ltd is pleased to announce the successful award of $936,000…
Adelaide, Australia GPN Vaccines is pleased to announce that Dr Erin Brazel has been awarded a Junior Fellowship…
Adelaide, Australia GPN Vaccines Ltd, a clinical-stage biotechnology company developing a Streptococcus pneumoniae vaccine to prevent life-threatening pneumonia, bacteraemia…
Adelaide, Australia, 8th August 2023 GPN Vaccines is pleased to announce our recent success in the Australian Government’s…
